Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218171 | 0.81 | ATM (0.43) | MEN1KMT2AATMTGFBR1GRM5 | |
| SCHEMBL4434519 | 0.81 | MAPK14 (0.53) | MEN1KMT2AATMALOX5MAPK14 | |
| SCHEMBL4434524 | 0.81 | MAPK14 (0.53) | MEN1KMT2AATMALOX5MAPK14 | |
| SCHEMBL4434551 | 0.81 | ALOX5 (0.61) | MEN1KMT2AATMALOX5MAPK14 | |
| SCHEMBL6975683 | 0.80 | TGFBR1 (0.54) | MEN1KMT2AATMTGFBR1MAPK14 | |
| SCHEMBL4084260 | 0.80 | TGFBR1 (0.61) | MEN1KMT2AATMTGFBR1MAPK14 | |
| SCHEMBL29624091 | 0.80 | TGFBR1 (0.61) | MEN1KMT2AATMTGFBR1MAPK14 | |
| SCHEMBL6979584 | 0.78 | TGFBR1 (0.45) | MEN1KMT2AATMTGFBR1GRM5 | |
| SCHEMBL4082163 | 0.72 | MAPK14 (0.67) | MEN1KMT2AALOX5TGFBR1MAPK14 | |
| SCHEMBL6966236 | 0.72 | TGFBR1 (0.54) | TGFBR1GRM5MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| US-20080146617-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| WO-2008071605-A2 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| JP-2002541253-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | claimed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2024-03-14 | — | — | US | disclosed |
| EP-3133149-B1 | METHOD FOR PREPARING OSTEOBLASTS AND OSTEOBLAST INDUCER | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2022-06-22 | — | — | EP | disclosed |
| US-20220016100-A1 | Treatment of Hearing Loss by Inhibition of Casein Kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-01-20 | — | — | US | disclosed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | MEN1 3268/4885KMT2A 1706/4885ATM 1677/4885 |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | MEN1 2519/4885KMT2A 2312/4885ATM 2132/4885 |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | FABP4, MAPK1, MAP3K1 | MEN1 3794/4885KMT2A 1812/4885ATM 318/4885 |
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | MEN1 4610/4885KMT2A 3632/4885ATM 3799/4885 |
| US-20080146617-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | MEN1 4610/4885KMT2A 3632/4885ATM 3799/4885 |
| US-20220016100-A1 | Treatment of Hearing Loss by Inhibition of Casein Kinase 1 | GSK3B, GSKIP, BACE1 | MEN1 2519/4885KMT2A 2312/4885ATM 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.